undamentalytics Newsletter
Sign in

Mannkind Corp revenue

Mannkind Corp's revenue was $349m in fiscal 2025, up 22.2% on the year before. Since fiscal 2010 ($93,000) it has grown at a compound 73.1% a year. Over the last twelve months it was $394m.

Revenue history

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2010Dec 20102011Dec 20112012Dec 20122013Dec 20132014Dec 20142015Dec 20152016Dec 20162017Dec 20172018Dec 20182019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Revenue0000001751228636575100199286349394
Growth on the year before—−46.2%−30.0%−100.0%———−93.3%+137.2%+126.3%+3.3%+15.8%+32.2%+99.4%+43.5%+22.2%—
Gross profit——————158−5843505984178268322353
Gross margin——————90.2%−46.7%30.4%68.1%76.8%77.7%84.0%89.5%93.9%92.3%89.8%

Revenue as reported in the company's 10-K and 10-Q filings (for banks, net interest income plus non-interest income). Growth is left blank when the earlier figure was zero or negative.

Where the revenue comes from

Fiscal year to December 31, 2025
Products and services
Line of business Revenue YoY
Product Revenue $217M ▲ 21.3%
Royalty $128M ▲ 25.2%
Products $114M ▲ 38.6%
Licenses and services $107M ▲ 5.8%
Services $4.3M ▼ 6.2%
Manufacturing Services $1.6M ▼ 77.5%

These categories overlap or exclude eliminations, so shares aren't shown.

From Mannkind Corp's 10-K filed February 26, 2026, as tagged in the filing. View filing. Indented rows are part of the line above; their share is of that line. In the bars, the faint bar behind is the year before.

Revenue against peers

Biotechnology: the closest covered companies by revenue. Last twelve months.

CompanyRevenueGrowth3-year growth a year
Mannkind Corp $394m 30.5% 35.5%
Meiragtx Holdings plc $398m 948.3% 296.0%
Sinovac Biotech LTD $386m 6.8% 66.1%
Pharming Group N.V. $376m 26.6% —
Novavax Inc $414m -61.6% -36.3%
Ardelyx, Inc. $451m 16.8% 75.9%

Compare with peers

Head to head: MGTX vs MNKDMNKD vs SVAMNKD vs PHARMNKD vs NVAX

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Mannkind Corp's SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Mannkind Corp.